Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-06-01 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物2021年年度报告（修订版）
Annual Report Classification · 100% confidence The document is titled '2021 年年度报告' which translates to '2021 Annual Report'. It contains detailed sections typical of an annual report such as company overview, financial data, management discussion and analysis, corporate governance, and audit information. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial statements, management analysis, risk disclosures, and other comprehensive information expected in an annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-06-01 Chinese
前沿生物关于2021年年度报告的信息披露监管问询函的回复公告
Management Reports Classification · 95% confidence The document is a detailed response to a regulatory inquiry regarding the company's 2021 Annual Report. It discusses financial figures, product sales, market analysis, R&D progress, and risk disclosures related to the 2021 fiscal year. The content includes extensive financial data, management discussion, and analysis of business operations and risks, which are typical components of a Management Discussion and Analysis (MDA) section. The document is not the Annual Report itself but a regulatory inquiry response focusing on clarifications and supplementary disclosures related to the Annual Report. Given the detailed financial and operational analysis, the best fitting category is Management Reports (MDA).
2022-06-01 Chinese
前沿生物股东减持股份结果公告
Major Shareholding Notification Classification · 95% confidence The document is a shareholder announcement regarding the results of a shareholding reduction plan by a significant shareholder (南京晟功创业投资中心). It details the number of shares reduced, the percentage of total shares, the methods of reduction (block trades and competitive bidding), and confirms the completion of the reduction plan. There is no financial statement, earnings data, or management discussion. The document is a formal notification of shareholding changes by a major shareholder, fitting the definition of a Major Shareholding Notification (MRQ). The document length is short (1671 characters), and it is not an announcement of a report publication but a substantive announcement of shareholding changes. Therefore, the correct classification is MRQ with high confidence.
2022-05-27 Chinese
前沿生物关于完成董事会、监事会换届选举及聘任高级管理人员、证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the completion of the board of directors and supervisory board re-election, appointment of senior management personnel, and securities affairs representative. It details the election results, committee appointments, and management hires following the 2021 annual general meeting held on May 24, 2022. The content focuses on governance changes and personnel appointments rather than financial results or reports. There is no indication of financial statements or earnings data. The document is a formal announcement of board and management changes, fitting the category of Board/Management Information (MANG). The document length is 4209 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2022-05-24 Chinese
瑞银证券有限责任公司关于前沿生物药业（南京）股份有限公司2021年度持续督导跟踪报告
Regulatory Filings
2022-05-24 Chinese
前沿生物关于第三届监事会第一次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resolution of the first meeting of the third Supervisory Board of the company. It details the election of the chairman of the Supervisory Board and the meeting procedures. There is no financial data, no mention of financial results, no audit report, no regulatory certification, or any other report type. It is a formal announcement about board/management changes, specifically about the Supervisory Board chairman election. This fits the category of Board/Management Information (MANG). The document length is short and focused on governance changes, not a report or announcement of a report publication.
2022-05-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.